Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8194 | 0.77 | ALDH1A1 (0.67) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL30099834 | 0.77 | ALDH1A1 (0.67) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL29663058 | 0.76 | ALDH1A1 (0.54) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| Formaldehyde SCHEMBL27344975 | 0.75 | ALDH1A1 (0.57) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL276403 | 0.74 | ALDH1A1 (0.52) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL3704751 | 0.74 | ALDH1A1 (0.63) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL28519048 | 0.74 | ALDH1A1 (0.63) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL3710107 | 0.74 | ALDH1A1 (0.63) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL29592061 | 0.74 | ALDH1A1 (0.63) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| Hydrogen Sulfide SCHEMBL29184282 | 0.74 | ALDH1A1 (0.63) | ALDH1A1CYP3A4MAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4151218-A1 | LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS | Boehringer Ingelheim International GmbH (DE) | 2023-03-22 | — | — | EP | claimed |
| EP-4104838-A1 | Use of DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | claimed |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-06-16 | — | — | US | claimed |
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| CN-112656945-A | Treatment of diabetes in patients unsuited for metformin therapy | 勃林格殷格翰国际有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-07-16 | — | — | US | claimed |
| EP-3626238-A1 | DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| US-20190202833-A1 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-04 | — | — | US | claimed |
| CN-101460173-A | Use of DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2009-06-17 | — | — | CN | claimed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022008-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022010-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| EP-2015754-A2 | USES OF DPP-IV INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-01-21 | — | — | EP | claimed |
| EP-1720875-B1 | 8- [3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-12-10 | — | — | EP | claimed |
| US-20070281940-A1 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-06 | — | — | US | claimed |
| WO-2007128761-A2 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-15 | — | — | WO | claimed |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | ALDH1A1 648/4885CYP3A4 175/4885MAPT 4367/4885 |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | ALDH1A1 412/4885CYP3A4 78/4885MAPT 2786/4885 |
| US-20070281940-A1 | USES OF DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | ALDH1A1 608/4885CYP3A4 179/4885MAPT 4278/4885 |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | ALDH1A1 648/4885CYP3A4 175/4885MAPT 4367/4885 |
| US-20190202833-A1 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | DPP4, DPP3, DPP7 | ALDH1A1 2418/4885CYP3A4 147/4885MAPT 3614/4885 |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | DPP8, DPP4, DPP7 | ALDH1A1 249/4885CYP3A4 88/4885MAPT 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.